60 Degrees Pharmaceuticals $SXTP: Commercial-Stage Infectious Disease Biotech with FDA-Approved ARAKODA® Reports Q1 Results 60 Degrees Pharmaceuticals reported Q1 2026 results, highlighting a revenue-generating biotech platform anchored by ARAKODA®, its FDA-approved malaria prevention product commercially available in the U.S. and Australia. Key Q1 2026 Investor Takeaways: • $162K in net product revenue, remaining relatively stable year-over-year • FDA-approved ARAKODA® continues to provide a commercial foundation • Active focus on infectious diseases and vector-borne illness, a global healthcare category with long-term relevance • U.S. and Australia commercial availability expands the company’s international footprint For biotech investors, $SXTP stands out as an emerging infectious disease company with an approved product already on the market, existing revenue, and a focused strategy in a specialized healthcare niche. Read the full Q1 2026 results: $SXTP $GDRX $VRTX $LLY $NVO $PFE $VALN $REGN

COMING SOON: @SKKN Resurfacing Pumpkin Enzyme Mask and Treatment Brush. Developed with cutting-edge biotechnology, our rinse-off exfoliating mask launches on October 4th alongside our application brush. Join the waitlist at the link in bio to shop first.

🚀 BiFinance IPO Series | 天辰生物-B HK STOCK IPO 👉 As a biotechnology company focused on innovative drug development, 天辰生物-B is committed to creating globally best-in-class and first-in-class therapies for cancer and other serious diseases. 🧬 Biotech × HK Stock IPO 🌍 Bridging Traditional Finance and Web3 📈 IPO Price: 96.06 HKD ⏰ Subscription Starts: 2026/5/28 9:00 Innovation in biotechnology is accelerating toward global capital markets, reshaping the future of healthcare and finance. #BiFinance# #IPO# #HKStocks# #Biotech# #Web3#

From the America Innovates stage, Timothy Springer, biotech founder, investor, and honoree on the Forbes 250 America’s Greatest Living Innovators list, on the medical advances helping keep cancer patients alive. ⠀ #Forbes250# #A250#

Suma Krishnan, Founder & President of Krystal Biotech, which is developing genetic medicines for rare diseases, on using AI to help automate business and manufacturing processes. ⁣ From the @america250 x Forbes America Innovates stage.⁣ ⁣ #Forbes250# #A250#

If Hantavirus mutated into a global threat, it would unleash AI + biotech unlike anything we've ever seen. > genome sequenced and public in 4 hours > AlphaFold maps every protein target > AI screens 10,000 drugs in 24 hrs > 50 vaccine candidates designed simultaneously > AI designed antibodies in days > risk of death computed instantly > decentralized trials launch globally > enroll from home > 20 countries manufacturing at once > first doses in three weeks > real-time dose characterization > your genome + biomarkers determine your protocol > variant map updates every hour No one would wait for governments.